Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Declines By 15.8%

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 9,212,055 shares, a decrease of 15.8% from the February 26th total of 10,935,571 shares. Based on an average daily trading volume, of 4,115,761 shares, the days-to-cover ratio is presently 2.2 days. Approximately 2.8% of the shares of the company are short sold.

Hedge Funds Weigh In On GoodRx

Large investors have recently made changes to their positions in the business. Alpine Global Management LLC purchased a new stake in GoodRx during the fourth quarter valued at about $177,000. Virtu Financial LLC lifted its position in shares of GoodRx by 903.3% in the 4th quarter. Virtu Financial LLC now owns 133,886 shares of the company’s stock valued at $363,000 after acquiring an additional 120,542 shares in the last quarter. Invesco Ltd. grew its position in GoodRx by 48.8% during the 4th quarter. Invesco Ltd. now owns 186,534 shares of the company’s stock worth $506,000 after purchasing an additional 61,193 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in GoodRx during the 4th quarter valued at $51,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of GoodRx in the fourth quarter valued at $44,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Price Performance

NASDAQ GDRX traded up $0.05 on Wednesday, reaching $2.01. 1,645,192 shares of the stock traded hands, compared to its average volume of 3,053,683. The firm’s fifty day simple moving average is $2.24 and its 200 day simple moving average is $2.93. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.78. The company has a market cap of $688.57 million, a price-to-earnings ratio of 22.34, a P/E/G ratio of 1.32 and a beta of 1.52. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The company had revenue of $194.79 million for the quarter, compared to the consensus estimate of $193.27 million. During the same quarter in the previous year, the business earned $0.09 EPS. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, research analysts predict that GoodRx will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GDRX shares. Wells Fargo & Company cut their target price on GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Citigroup decreased their price target on GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Jefferies Financial Group cut shares of GoodRx to a “hold” rating in a research note on Thursday, January 22nd. Mizuho reduced their price objective on shares of GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, February 27th. Finally, Morgan Stanley decreased their target price on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.98.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.